

## AG-14361

**Catalog #:** 27602-3

**Size:** 50 mg


**CAS Registry #:** 328543-09-5

**Purity:** ≥98% by HPLC

**Chemical Formula:** C<sub>19</sub>H<sub>20</sub>N<sub>4</sub>O

**Molecular Weight:** 320.4

**Structure:**



**Description:** AG14361 is a potent inhibitor of PARP1 with  $K_i$  of <5 nM. It is at least 1000-fold more potent than the benzamides. AG14361 treatment before irradiation statistically significantly increases the sensitivity to radiation therapy. AG14361 enhances the growth-inhibitory and cytotoxic effects of topoisomerase I poisons and increases the persistence of camptothecin-induced DNA single-strand breaks.

**Background:** A 17-hour exposure of A549 cells to 0.4  $\mu$ M AG14361 does not change the expression of the 6800 genes. Thus, although 0.4  $\mu$ M AG14361 inhibits cellular PARP-1 activity by more than 85%, it essentially does not change gene expression and cell proliferation, indicating that the cellular effects of this low concentration of AG14361 are specific for PARP-1 inhibition. Higher, growth-inhibitory concentrations of AG14361 affects gene expression, but these effects are not likely to be related to PARP-1 inhibition because cell proliferation is affected equally in PARP-/- and PARP-1+/+ cells.

**Biological Activity:** The IC<sub>50</sub> for AG14361 is 29 nM in permeabilized SW620 cells and 14 nM in intact SW620 cells.

**Solubility:** Soluble in DMSO. Solubility in water or ethanol is <1 mg/ml

**Storage/Stability:** Store at or below -20 °C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day. *Avoid freeze/thaw cycles.*

**References:**

1. Smith LM, *et al. Clin Cancer Res.* 2005 Dec 1; **11(23)**:8449-57.
2. Calabrese CR, *et al. J Natl Cancer Inst.* 2004 Jan 7; **96(1)**:56-67.